Compare Amylx Pharmaceuticals Inc (AMLX) vs Angi Inc (ANGI) Price & Performance

AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.

The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.

ANGI trades at $4.315, down 5.99% in the last session, reflecting ongoing operational challenges. The stock shows bearish technical signals with support near $4.00 and resistance at $5.00. Recent Q2 2026 earnings missed expectations with a significant EPS loss of $5.70, while revenue declined 11% year-over-year. Despite a low P/E of 14.81 and P/S of 0.19, negative net income margin of -22.35% and ROE of -26.25% highlight profitability struggles. Analyst consensus remains mixed with a $7.00 price target but accelerating pro user churn and legal investigations cloud the outlook.

The outlook for ANGI is cautious due to declining revenue, persistent losses, and competitive pressures. Investment opportunity exists if the company successfully executes its AI pivot and stabilizes user engagement, but risks include ongoing legal probes, high debt, and market share erosion. Near-term volatility is likely amid weak fundamentals and negative sentiment.